Artivion (NYSE:AORT) Stock Price Up 8.2% – What’s Next?

Artivion, Inc. (NYSE:AORT) shares rose 8.2% during trading on Tuesday . The company traded as high as $28.56 and last traded at $28.4550. 380,290 shares were traded during mid-day trading, a decline of 35% from the average daily volume of 589,164 shares. The stock had previously closed at $26.31.

Analyst Ratings Changes

AORT has been the topic of several recent research reports. Wall Street Zen cut Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Citizens Jmp dropped their target price on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a report on Friday, May 8th. Stifel Nicolaus set a $45.00 price target on shares of Artivion in a research report on Monday, June 1st. Canaccord Genuity Group set a $39.00 price objective on shares of Artivion in a research note on Friday. Finally, Weiss Ratings lowered shares of Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, June 8th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Artivion currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.67.

Artivion Stock Up 8.3%

The company has a debt-to-equity ratio of 0.82, a current ratio of 3.47 and a quick ratio of 2.51. The stock has a 50 day simple moving average of $23.63 and a 200-day simple moving average of $30.92. The firm has a market cap of $1.38 billion, a PE ratio of -407.17 and a beta of 1.24.

Artivion (NYSE:AORT) last released its earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%.The firm had revenue of $125.76 million for the quarter, compared to analysts’ expectations of $119.99 million. Sell-side analysts predict that Artivion, Inc. will post 0.45 EPS for the current fiscal year.

Insider Transactions at Artivion

In related news, SVP Andrew M. Green sold 44,001 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $20.70, for a total transaction of $910,820.70. Following the sale, the senior vice president directly owned 60,259 shares of the company’s stock, valued at approximately $1,247,361.30. This represents a 42.20% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Royal Bank of Canada grew its holdings in shares of Artivion by 107.0% during the first quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock valued at $952,000 after buying an additional 20,010 shares during the last quarter. AQR Capital Management LLC raised its holdings in Artivion by 8.8% in the 1st quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock worth $862,000 after acquiring an additional 2,823 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Artivion by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock valued at $580,000 after acquiring an additional 1,032 shares in the last quarter. Creative Planning lifted its position in Artivion by 5.6% in the 2nd quarter. Creative Planning now owns 14,272 shares of the company’s stock valued at $444,000 after acquiring an additional 753 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in Artivion by 40.8% during the 2nd quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock valued at $14,960,000 after purchasing an additional 139,370 shares during the last quarter. 86.37% of the stock is owned by hedge funds and other institutional investors.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.